This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

WDVAX

Dana-Farber/Harvard Cancer Center

Drug Names(s): Dendritic Cell Activating Scaffold, WDVAX

Deal Structure: WDVAX is an aspirin-sized disk containing autologous melanoma cells taken from the patient. The cells are freeze/thawed to generate a tumor lysate which is then combined with the immune stimulating agents, GM-CSF and CpG, and a protein adhesive, PLGA, to form a disk-like sponge that can be implanted under the skin.

The disk is designed to stimulate the immune system against melanoma antigens in the lysate.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug